EVT.F : Summary for EVOTEC AG O.N. - Yahoo Finance

U.S. Markets close in 6 hrs 30 mins

Evotec AG (EVT.F)


Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
6.34+0.14 (+2.19%)
As of 7:48 AM EST. Market open.
People also watch:
MOR.FEVT.DEPA8.FIFX.FSNG.F
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close6.20
Open6.19
Bid0.00 x 400000
Ask0.00 x 400000
Day's Range6.18 - 6.37
52 Week Range2.87 - 6.37
Volume31,631
Avg. Volume31,509
Market Cap826.48M
BetaN/A
PE Ratio (TTM)48.73
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire8 hours ago

    Evotec and Forge Therapeutics Form Strategic 'Superbug' Alliance

    Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections including those caused by drug resistant 'superbugs'.

  • PR Newswire8 hours ago

    Forge Therapeutics and Evotec Form Strategic 'Superbug' Alliance

    SAN DIEGO, Dec. 9, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative antibiotic program targeting 'LpxC' for the treatment of bacterial infections including those caused by drug resistant 'superbugs'. Forge has been applying its proprietary metal-binding pharmacophores ("MBP") library and processes and has been able to identify potent druggable inhibitors of LpxC. The alliance will be focused on lead optimization of these inhibitors with the goal of identifying a development candidate in the next couple of years.

  • Business Wire9 days ago

    Evotec and Merck Enter into Agreements to Collaborate on Target Discovery Technologies

    Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile screening platforms and disease expertise.